Rossari Biotech Reports Q3 Profit Amid 52-Week Low Stock Price; Revenue, EBITDA Up

• Rossari Biotech Ltd announced its Q3 results, showing a net profit increase from ₹31.7 crore to ₹32.7 crore year-on-year.
• The company's EBITDA also rose from ₹64.7 crore to ₹68.8 crore, indicating improved operational performance.
• Despite profit and revenue growth, the EBITDA margin declined from 12.6% to 11.8% due to rising costs and pricing pressure.
• The stock is currently trading at a 52-week low, raising investor concern despite positive financial results.

Why It Matters: Rossari Biotech posted Q3 profit and revenue growth, but margin pressure remains a key investor concern.